ストックスクリーナーアプリを入手
12.77
1.69%
-0.23
前日終値:
$13.00
開ける：
$13
24時間の取引高:
1.49M
Relative Volume:
0.32
時価総額：
$813.51M
収益：
-
当期純損益:
$-145.21M
株価収益率:
-5.5522
EPS:
-2.3
ネットキャッシュフロー:
$-140.12M
1週間 パフォーマンス:
+0.08%
1か月 パフォーマンス:
+39.52%
6か月 パフォーマンス:
-66.84%
1年 パフォーマンス:
-75.36%
1日の値動き範囲:
$12.43
$13.19
1週間の範囲:
$12.43
$13.99
52週間の値動き範囲:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
MLTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
12.77 | 921.02M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.06 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.11 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
437.57 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.65 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.09 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-03 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | ダウングレード | Goldman | Buy → Neutral |
| 2025-09-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-09-30 | ダウングレード | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2025-09-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-28 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Moonlake Immunotherapeutics stock price target lowered to $26 at H.C. Wainwright - Investing.com India
MoonLake Immunotherapeutics Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - Stock Titan
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join - GlobeNewswire
MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action Deadline - MarketScreener
DEADLINE ALERT for ATYR, MLTX, BAX, JHX: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - FinancialContent
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MLTX LAWSUIT ALERT: The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
MLTX LEGAL REMINDER: MoonLake Immunotherapeutics Faces Securities Allegations over Drug Trial Results -- Investors Alerted to Contact BFA Law before December 15 - ACCESS Newswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LONGSTANDING LAW FIRM, Encourages MoonLake - GlobeNewswire
MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
The Gross Law Firm Notifies MoonLake Immunotherapeutics - GlobeNewswire
MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline - Newsfile
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - Barchart.com
Holdings of MoonLake Immunotherapeutics (MLTX) are aligned with the stars - Setenews
MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 Deadline - Newsfile
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out - Yahoo Finance
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - news.stocktradersdaily.com
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities ViolationsContact Levi & Korsinsky Today - Newsfile
MLTX DEADLINE REMINDER: MoonLake Immunotherapeutics 90% Stock Drop Triggers Securities Fraud Class ActionInvestors Urged to Contact BFA Law by December 15 - ACCESS Newswire
MLTX MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - MarketScreener
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action LawsuitRGRD Law - GlobeNewswire
MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline - Eastern Progress
MoonLake Immunotherapeutics Stock: Ignore The Panic, Catch The Upside (NASDAQ:MLTX) - Seeking Alpha
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit - Morningstar
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, - GlobeNewswire
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of December 15, 2025 Deadline - MarketScreener
MLTX STOCK LOSS: MoonLake Immunotherapeutics Faces - GlobeNewswire
MLTX Stockholders Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
United StatesMintz Advises On MoonLake Immunotherapeutics’ $75 Million Offering - Mondaq
Quantitative breakdown of MoonLake Immunotherapeutics recent moveStock Surge & Risk Adjusted Buy/Sell Alerts - newser.com
ROSEN, TOP-RANKED INVESTOR RIGHTS COUNSEL, Encourages MoonLake Immunotherapeutics Investors to ... - Bluefield Daily Telegraph
2025-11-16 | Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025Contact Levi & Korsinsky | NDAQ:MLTX | Press Release - Stockhouse
MoonLake Immunotherapeutics Completes $75 Million Follow-on Equity Offering - Global Legal Chronicle
News impact scoring models applied to MoonLake ImmunotherapeuticsPortfolio Update Summary & Short-Term Trading Alerts - newser.com
MLTX Shareholders Have Opportunity to Lead MoonLake Immunotherapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
MoonLake Immunotherapeutics (MLTX) Investors are Reminded to Contact BFA Law Before the December 15 Securities Fraud Class Action Deadline - MarketScreener
Will MoonLake Immunotherapeutics stock benefit from automation2025 Price Action Summary & High Conviction Investment Ideas - newser.com
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
Moonlake Immunotherapeutics (MLTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
1.64%
0.70%
大文字化:
|
ボリューム (24 時間):